Past, present, and future clinical trials of cardiovascular risk reduction—the hyperlipidemia perspective

  • Poulter N
  • 2


    Mendeley users who have this article in their library.
  • 2


    Citations of this article.


In the 1990s, several randomized trials showed that long-term intervention with statin therapy reduces mortality and recurrent ischemic cardiovascular events both in individuals at increased risk of coronary heart disease (CHD) and in patients with established CHD. Since then, additional trials have illustrated the benefits of statin therapy in a variety of other high-risk patient populations. The HPS and ASCOT-LLA trials showed beneficial effects of statins in individuals with below average, average, or moderately elevated LDL cholesterol levels. The results of the ASCOT-LLA appear to conflict with those of the ALLHAT-LLT study, both of which were carried out among patients with hypertension. In the ALLHAT-LLT trial, significant cardiovascular benefits associated with statin use were not apparent. However, this appears to relate to the inadequate relative reduction in LDL and total cholesterol achieved. The cardiovascular benefits of statins also extend to the elderly and patients with diabetes. This review presents the latest data. © 2003 Elsevier B.V.

Author-supplied keywords

  • Cholesterol
  • Coronary heart disease
  • Diabetes
  • Hypertension
  • Statins

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Neil R. Poulter

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free